Arylacetamide deacetylase-like 3 (AADACL3)

Arylacetamide deacetylase-like 3 (AADACL3) is a predicted membrane-associated lipolytic enzyme that belongs to the arylacetamide deacetylase family. It is believed to have carboxylic ester hydrolase activity and likely plays a role in lipid catabolism and deposition[1]. Genomic studies have indicated that altered AADACL3 expression or mutation may affect fat deposition in livestock and may be connected to immunopathological processes in humans, possibly due to changes in lipid processing. While its detailed substrate specificity and complete biological function are not fully established, AADACL3’s family members (notably AADAC) are well-characterized for involvement in both lipid and drug metabolism and are linked to disease phenotypes such as metabolic disorders and certain skin diseases[1][4]. If more precise information about AADACL3’s endogenous or pharmacologic substrates becomes available in the future, it will likely further clarify therapeutic opportunities and biomarker relevance.

Other names

AADACL3OTTHUMG00000001887arylacetamide deacetylase-like 3ADCL3_HUMAN

Not established for AADACL3. By analogy to other arylacetamide deacetylases, mechanism may involve hydrolysis (deacetylation) of ester or amide bonds in drugs or endogenous substrates[1].